Document Detail

Anakinra (interleukin-1 receptor antagonist) has positive effects on function and quality of life in patients with rheumatoid arthritis.
MedLine Citation:
PMID:  16751154     Owner:  NLM     Status:  MEDLINE    
Rheumatoid arthritis (RA) has severe and lasting effects on quality of life. This review (1) describes the disease progression, disability, and joint destruction that seriously alter a patient's quality of life, and (2) explains how the interleukin-1 receptor antagonist (IL-1Ra), anakinra, retards the progress of disease, thereby improving outcomes. Relevant articles were reviewed with a focus on RA, anakinra, and functional and quality-of-life outcomes. In randomized, controlled trials, the IL-1Ra anakinra provided meaningful benefits for patients with active RA, such as decreased signs and symptoms of disease, slower radiographic disease progression, reduced disability, and improved health-related quality of life. The biologic agent, anakinra, provides to patients with RA a valuable treatment option that has a positive impact on both function and quality of life.
Arthur Kavanaugh
Related Documents :
15570644 - Prolactin and growth hormone responses to hypoglycemia in patients with rheumatoid arth...
7783054 - Soluble receptors for tumor necrosis factor and interleukin-2 in serum and synovial flu...
15833144 - Modulating co-stimulation: a rational strategy in the treatment of rheumatoid arthritis?
20461784 - Radiographic severity of rheumatoid arthritis in african americans: results from a mult...
755654 - The prevalence of nickel allergy among women. an epidemiological study in hospitalized ...
19394004 - Deep sedation with propofol does not precipitate hepatic encephalopathy during elective...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Review    
Journal Detail:
Title:  Advances in therapy     Volume:  23     ISSN:  0741-238X     ISO Abbreviation:  Adv Ther     Publication Date:    2006 Mar-Apr
Date Detail:
Created Date:  2006-06-05     Completed Date:  2006-07-05     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8611864     Medline TA:  Adv Ther     Country:  United States    
Other Details:
Languages:  eng     Pagination:  208-17     Citation Subset:  T    
Center for Innovative Therapy, Division of Rheumatology, Allergy, and Immunology, University of California, San Diego, La Jolla, California 92093-0943, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antirheumatic Agents / administration & dosage,  therapeutic use*
Arthritis, Rheumatoid / drug therapy*,  psychology
Interleukin 1 Receptor Antagonist Protein
Quality of Life*
Randomized Controlled Trials as Topic
Receptors, Interleukin-1 / antagonists & inhibitors*
Recombinant Proteins / administration & dosage,  therapeutic use*
Sialoglycoproteins / administration & dosage,  therapeutic use*
Reg. No./Substance:
0/Antirheumatic Agents; 0/IL1RN protein, human; 0/Interleukin 1 Receptor Antagonist Protein; 0/Receptors, Interleukin-1; 0/Recombinant Proteins; 0/Sialoglycoproteins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Cost-effectiveness of basal insulin from a US health system perspective: comparative analyses of det...
Next Document:  Autologous platelet-rich plasma for wound and osseous healing: a review of the literature and commer...